The author describes a 21-year-old woman with persistent disabling
dysmorphophobia (atypical somatoform disorder) that failed to respond to
neuroleptics and heterocyclic antidepressants but resolved completely with
the monamine oxidase inhibitor tranylcypromine.
Abstract Teaser